The systems and methods of the present disclosure can be used to generate systems and models that are physiologically relevant to the human and animal system. These physiological conditions can be designed to mimic the actual human condition for cell differentiation and proliferation. The system and methods of this present disclosure allow the formation of an appropriate biomaterial to mimic that which exists in a human or animal scaffold. Utilizing 3D printing technology, a hydrogel scaffold can be printed at various resolution very close to human physiological geometry. Additionally, the architecture can be optimized for the selected application and appropriate cells can be seeded on the scaffold prior to testing.

Systems and methods for tissue engineered synthetic support structures, such as grafts and patches are provided. The systems and methods can be used to make tissue engineered planar sheathes or meshes that can be fashioned into substantially planar or non-planar 3D tissue/organ structures adaptable to structure and organs within a human or mammalian body. The systems and methods can use bioink deposited on a material having specified properties and matured under specified conditions to create the tissue engineered planar sheathes or meshes having biomechanical and biological properties tailored to a particular tissue.

Composites based on a polymer and a mixture of proteins derived from a MaSp (major ampullate spidroin) protein are provides. Further, methods for preparation of same, and method of use of the composites are provided.

The disclosure relates to methods, systems and compositions for use in the production of milk. More specifically, the disclosure is directed to systems, compositions and methods for in-vitro production of milk using an array of mammary organoids seeded on tertiary-branched, resilient duct scaffolding.

A modular engineered tissue construct includes a plurality of fused self-assembled, scaffold-free, high-density cell aggregates. At least one cell aggregate includes a plurality of cells and a plurality of biocompatible and biodegradable nanoparticles and/or microparticles that are incorporated within the cell aggregates. The nanoparticles and/or microparticles acting as a bulking agent within the cell aggregate to increase the cell aggregate size and/or thickness and improve the mechanical properties of the cell aggregate as well as to deliver bioactive agents.

According to the present invention, there are provided a chamber for transplantation, as a planar chamber for transplantation which has a structure in which membranes for immunoisolation face each other, and which is capable of stably enclosing a biological constituent, including a membrane for immunoisolation at a boundary between an inside and an outside of the chamber for transplantation, in which the membranes for immunoisolation which face each other have joint portions that are joined to each other, an interior space includes a point at a distance of 10 mm or longer from any position of the joint portion, and the membrane for immunoisolation has flexibility that allows a distance of 1 mm to 13 mm as the following distance: in a case where a portion of 10 mm from a side surface of one short side of a 10 mm×30 mm rectangular test piece of the membrane for immunoisolation is vertically sandwiched between flat plates, and the flat plates are placed horizontally, a distance between a horizontal plane including a center plane in a thickness direction of the sandwiched portion of the membrane for immunoisolation, and a part, which is farthest from the horizontal plane, of a residual 20 mm-portion projecting from the flat plate; and a device for transplantation including the chamber for transplantation enclosing a biological constituent therein.

The invention provides a substrate for producing cell aggregates provided with a spot(s) comprising a copolymer containing recurring units derived from monomers represented by the following formulae (I) and (II):

##STR00001##

wherein U.sup.a1, U.sup.a2, R.sup.a1, R.sup.a2 and R.sup.b are as defined herein, on a substrate having an ability to inhibit adhesion of cells, wherein a completion time of forming cell aggregates after seeding cells is within 20 hours.

The present disclosure provides a method of producing uniformly sized organoids/multicellular spheroids using a microfluidic device having an array of microwells. The method involves several successive steps. First, a microfluidic device containing parallel rows of microwells that are connected with a supplying channel is filled with a wetting agent. The wetting agent is a liquid that is immiscible in water. For example, the wetting agent may be an organic liquid such as oil. In the next step, the agent in the supplying channel and the microwells is replaced with a suspension of cells in an aqueous solution that contains a precursor for a hydrogel. Next, the aqueous phase in the supplying channel is replaced with the agent, which leads to the formation of an array of droplets of cell suspension in the hydrogel precursor solution, which were compartmentalized in the wells. The droplets are then transformed into cell-laden hydrogels. Subsequently, the agent in the supplying channel is replaced with the cell culture medium continuously flowing through the microfluidic device and the cells within the hydrogels are transformed into multicellular spheroids.

3D native tissue-derived scaffolding materials are made in various formats, including but not limited to hydrogel, sponge, fibers, microspheres, and films, all of which function to better preserve natural extracellular matrix molecules and to recapitulate the natural tissue environment, thereby effectively guiding tissue regeneration. Tissue-derived scaffolds are prepared by incorporating a homogenized tissue-derived suspension into a polymeric solution of synthetic, natural, or hybrid polymers. Such tissue-derived scaffolds and scaffolding materials have a variety of utilities, including: the creation of 3D tissue models such as skin, bone, liver, pancreas, lung, and so on; facilitation of studies on cell-matrix interactions; and the fabrication of implantable scaffolding materials for guided tissue formation in vivo. The tissue-derived scaffolds and scaffolding materials also provide the opportunity to correlate the functions of extracellular matrix with tissue regeneration and cancer metastasis, for example.

Described herein is a beads-free bioprocessor as an automated and cost-effective T cell processing and manufacturing platform. T cells are a core component in CAR T cell therapies for cancer treatment, but are difficult to manufacture to scale in clinically relevant quantities. The 3D bioprocessor provides an alternative device that is scalable, beads-free, easy-to-use, and cost-effective for using CAR T cell therapy in cancer immunotherapy. Besides CAR T cell application, this platform technology has potential for many other applications such as cancer cell isolation.